Celgene

Celgene

Metrics Value

Newsweek Green Score

2015 = 44.8 /100

Employees (G4-10-a)

2014 = 6,379 employees

Indirect greenhouse gas (GHG) emissions (Scope 2) (G4-EN16-a)

2014 = 14,939 tonnes CO2 equivalent

Environmental Fines (G4-EN29-a)

2014 = $ 0

Energy Productivity

2015 = 0 %

Labor Practices Screening of New Suppliers (G4-LA14-a)

2014 = Unknown %

Greenhouse Gas (GHG) emissions intensity ratio (G4-EN18-a)

2014 = 5 : 1

Female employees (G4-10-a)

2014 = Unknown employees

Total Water Withdrawals (G4-EN8-a)

2014 = 391,543 cubic metres

Hazardous Waste Recycled (G4-EN23-a)

2014 = Unknown tonnes

Unrecognized Tax Benefits Reductions Resulting from Lapse of Applicable statute of Limitations

2015 = $ 10.8M

Undistributed Earnings of Foreign Subsidiaries

2015 = $ 9.67B

Volatile Organic Compounds (VOC) emissions (G4-EN21-a)

2014 = Unknown tonnes

Male employees (G4-10-a)

2014 = Unknown employees

Employees engaged in lobbying

2014 = 4 people

Effective Income Tax Rate Continuing Operations

2015 = 0.208

Good Will

2015 = $ 4.88B

Net Income Attributable to Non Controlling Interest

2013 = $ 0

Cost of Goods and Services Sold

2010 = $ 307M

Current Foreign Tax Expense Benefit

2015 = $ 71.1M
+Wikipedia
Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals.